Summary: Nateglinide is an antidiabetic agent metabolized by CYP2C9 and CYP3A4; hence inhibitors of these CYP isozymes may interact with nateglinide. There are, however, only limited in vitro data on how to predict drug-drug interactions in vivo. We examined the eŠects of 18 drugs that may be prescribed together with nateglinide (metformin, buformin, aspirin, gemˆbrozil, simvastatin, pioglitazone, rosiglitazone, carbamazepine, clarithromycin, gliclazide, cloˆbrate, ‰uconazole, bezaˆbrate, phenylbutazone, nifedipine, famotidine, ibuprofen and miconazole) on the conversion of nateglinide to its major metabolite (N-[trans-4-(1-hydroxy-1-methylethyl)-cyclohexanecarbonyl]-D-phenylalanine) using human liver microsomes. Eight compounds showed aº50z inhibitory eŠect and we estimated the Ki values for the remaining 10 compounds. Except for ‰uconazole and miconazole, 1＋Iin, max, u/Ki calculated from the Ki values, was approximately 1 and thus the possibility of a drug-drug interaction was considered low. The value for ‰uconazole suggested the risk of interaction and agreed with the results of clinical studies in which the AUC of nateglinide increased by 48z when it was co-administered with ‰ucona-zole. The present study showed that nateglinide metabolism would hardly be aŠected by the drugs used in this study, except for miconazole and ‰uconazole that are potent inhibitors of multiple isoforms of CYPs.
Introduction
Nateglinide is a widely used type 2 antidiabetic agent that promotes insulin secretion and reduces hyperglycemia after meals. This drug is known to be metabolized in the liver, mainly by CYP2C9 and partially by CYP3A4.
1) The main metabolite of nateglinide in humans is N-[trans-4-(1-hydroxy-1-methylethyl)-cyclohexanecarbonyl]-D-phenylalanine (hereinafter abbreviated as M1) and at least additional 8 metabolites have been detected in human plasma and urine.
2)
The drug induced suŠering due to concomitant administration of sorivudine (anti-virus agent) and oral 5-‰uorouracil prodrugs (anti-cancer agent) became a serious problem.
3) This drug-drug interaction is caused by the inhibition of metabolizing enzyme (dihydropyrimidine dehydrogenase), but the clinically problematic interactions often appear via cytochrome P450 enzymes (CYPs). Until now there have been various reports on drug-drug interactions catalyzed by CYP isozymes, and in clinical practice these interactions can be predicted based on in vitro experimental data with some certainty. 4, 5) Since CYP2C9 and CYP3A4 mediate the metabolism of nateglinide, inhibitors of these CYP isozymes may interact with nateglinide when concomitantly administered. The in vitro data on nateglinide from which drug-drug interactions via CYPs can be predicted are scarce. This study was intended to conˆrm using human liver microsomes, whether drugs that might be concomitantly administered with nateglinide would interact with nateglinide through enzymatic inhibition. The 18 inhibitors used in the present study include metformin, buformin, aspirin, gemˆbrozil, simvastatin, pioglitazone, rosiglitazone, carbamazepine, clarithromycin, gliclazide, cloˆbrate, ‰uconazole, bezaˆbrate, phenylbutazone, nifedipine, famotidine, ibuprofen and miconazole. These inhibitors were selected from a broad range of drugs with various eŠects and some of them in-hibit CYP3A4 and/or CYP2C9.
Materials and Methods
Chemicals and reagents: Nateglinide and M1 were synthesized by Ajinomoto Co., Inc. (Tokyo, Japan). Pioglitazone hydrochloride was supplied by Takeda Pharmaceutical Co., Ltd. (Osaka, Japan) or was obtained from Wuhan S & M Biochemie Ltd. (Hubei, China). Other chemicals were obtained from the following sources: buformin hydrochloride, simvastatin, clarithromycin, gliclazide and cloˆbrate were from Wako Pure Chemical Ind. (Osaka); metformin hydrochloride, aspirin, gemˆbrozil, carbamazepine, nifedipine, famotidine, ibuprofen and (±)-miconazole nitrate salt were from Sigma Chemical Co. (St Louis, MO); rosiglitazone maleate was from Wuhan S & M Biochemie Ltd.; ‰uconazole and bezaˆbrate were from ICN Biomedicals, Inc. (Cleveland, Ohio); phenylbutazone was from Lancaster Synthesis (Morecambe, UK). Pooled human liver microsomes from 10 or 50 individuals were obtained from Xeno Tech, LLC. (Kansas City, KS). Human CYP (CYP2C9 or CYP3A4) and human CYPreductase coexpressed in Escherichia coli were obtained from Cypex Ltd. (Dundee, UK). b-nicotinamide-adenine dinucleotide phosphate reduced form (b-NADPH), D-glucose 6-phosphate, disodium salt (G-6-P), and glucose-6-phosphate dehydrogenase from yeast (G-6-P DH) were obtained from Oriental Yeast Co., Ltd. (Tokyo). All solvents and other chemicals used were of HPLC grade or the highest purity commercially available.
In vitro study: After a solution prepared by mixing the ingredients shown below under ice-cold conditions was pre-incubated at 379 C for 5 min, 2.5 mL of a methanol or DMSO solution of each inhibitor (Solvent was added to samples which did not contain an inhibitor. However, no additives were used in the investigation of kinetic parameters.) and 5 mL of a 50z aqueous ethanol solution of nateglinide were added. The incubation mixture with aˆnal volume of 500 mL consisted of 0 to 2 mM inhibitor, 5 to 300 mM of nateglinide, 0.1 mM EDTA, 0.1 M potassium phosphate buŠer (pH 7.4), 0.8 or 1.2 mg/mL human liver microsomes (In the experiment using the E. coli expression system for human CYPs, 5 pmol/mL CYP3A4 or 10 pmol/mL CYP2C9 was used.), 2 mM b-NADPH, 19 mM G-6-P, 10 mM magnesium chloride hexahydrate, and 2 units of G-6-P DH. Theˆnal concentration of the organic solvent added to the incubation mixture was set at ≦1z. The reaction was allowed to proceed for 20 min or 30 min in experiments using human liver microsomes, or 12 min for CYP2C9 and 60 min for CYP3A4 in those using the E. coli expression system for human CYPs. The reaction was terminated by adding 300 mL of the reaction mixture to a test tube that contained 600 mL of acetonitrile. The mixture was centrifuged at 1500 g for 10 min. In studies using the E. coli expression system, supernatants were collected and used for the analyses. For other samples, 300 mL of the supernatant was pipetted into a tube and evaporated to dryness in a centrifugal evaporator. The dried residue was reconstituted with 100 mL of a mixture of acetonitrile/0.05 M (Na ＋ ) phosphate buŠer (pH 6.6) (14/86 volz). The solution was centrifuged at 15000 g for 5 min, and the supernatant was analyzed. These conditions were determined based on the results of a preliminary study so that M1 was generated in a linear manner.
The fraction of inhibitors unbound to human liver microsomes (fu, in vitro) was subjected to an ultracentrifugation method by referring to the HAB protocol. 6) Analysis of compounds: In experiments using human liver microsomes, M1, the major metabolite of nateglinide, was quantitated by an HPLC using Chromolith Speed ROD RP-18e 4.6×50 mm No. UM9438/054 (Merck, Darmstadt, Germany) as the column. After 20 mL of samples was injected, the eluate was monitored at 210 nm and a column temperature at 409 C. Two mobile phases were used for elution: mobile phase A consisting of acetonitrile/0.05 M (Na ＋ ) phosphate buŠer (pH 6.6) (14/86, volz) and mobile phase B consisting of acetonitrile/ethanol/0.05 M (Na ＋ ) phosphate buŠer (pH 6.6) (32/6/62, volz). The sample was eluted with mobile phase A 100z from 0 to 7.5 min and the composition of mobile phase was switched to A:B＝ 53: 47 at 7.5 min, then the sample was eluted for up to 30 min at a ‰ow rate of 1 mL/min. After the analysis, the column was washed with mobile phase B at a ‰ow rate of 5 mL/min and stabilized.
The concentration of M1 in experiments using the E. coli expression system, and the concentration of each inhibitory agent in the reaction mixtures using human liver microsomes were quantiˆed by LC/MS/MS. The LC system used for nifedipine was LC-10A HPLC series (Shimadzu Corporation, Kyoto, Japan), while that used for other compounds was Agilent 1100 HPLC Series (Agilent Technologies, Wilmington, DE). The MS/MS system used for nifedipine was API2000 system (Applied Biosystems, Foster City, CA), while that used for other inhibitors was API3000 system (Applied Biosystems). The columns used were Cadenza CD-C18 2 ×50 mm, 3 mm (Imtakt Corporation, Kyoto) for nifedipine, inertsil ODS-3 3 mm 2.1×100 mm (GL sciences) for M1 and Develosil ODS-UG-3 2×50 mm, 3 mm (Nomura Chemical Co., Ltd., Aichi, Japan) for other compounds. The columns were used at 509 C for nifedipine and 559 C for other compounds. The following mobile phases were used at a ‰ow rate of 0.5 mL/min for nifedipine and 0.3 mL/min for other compounds in a gradient manner: 25 mM (NH4 ＋ ) formate buŠer pH 6.0 (mobile phase A) and acetonitrile (mobile phase B) for nifedipine, 10 mM ammonium formate aqueous solution (mobile phase A) and acetonitrile (mobile phase B) for ibuprofen and gemˆbrozil, and an aqueous solution of 0.1z formic acid (mobile phase A) and acetonitrile containing 0.1z formic acid (mobile phase B) for other compounds. The gradient was performed as follows. M1: 20 min linear increase from 30z to 70z mobile phase B and 70z mobile phase B for 5 min; nifedipine: 5 min linear increase from 30z to 70z mobile phase B and 70z mobile phase B from 5.1 min to 10 min; gembrozil and ibuprofen: 5 min linear increase from 5z to 80z mobile phase B and 80z mobile phase B for 4 min followed by 5z mobile phase B from 9.01 min to 11 min; pioglitazone and rosiglitazone: 5 min linear increase from 10z to 60z mobile phase B and 60z mobile phase B for 1 min followed by 10z mobile phase B from 6.01 min to 7 min; other compounds: 6 min linear increase from 5z to 80z mobile phase B and 80z mobile phase B for 2 min followed by 5z mobile phase B from 8.01 min to 10 min. The operating conditions of MS/MS and internal standards used are summarized in Table 1 . All analytes were detected using the multiple reaction monitoring mode.
Calculation of IC 50, app and K i values:
The apparent values of 50z inhibitory concentration (IC50, app) and inhibition constant (Ki) were calculated basically by referring to the HAB protocol.
6) The ratio of concentration of M1 generated in the presence of each inhibitor to that in its absence was calculated as residual activity (z) for the respective inhibitors. The IC50, app value was calculated using WinNonlin Professional (Pharsight Corp., Mountain View, CA) by plotting the residual activity versus the concentration of the inhibitor. When the inhibition was º50z at the maximum concentration, the IC50, app value was deˆned to be more than the maximum concentration, and after the IC50, app value was determined, the Ki, app value was calculated by the Dixon plot. The inhibition constants obtained were apparent values (Ki, app) using spikingˆnal inhibitor concentrations as they were. The Ki value was calculated by multiplying the unbound fraction in the in vitro reaction system using human liver microsome (f u, in vitro ), because it has been generally thought that the unbound form of drugs is utilized in the enzymatic reaction.
Prediction of drug-drug interaction: We estimated the increasing rate of the AUC of nateglinide after concomitant administration of two drugs based on the 1＋ [I]/Ki (where [I]＝the concentration of the inhibitor adjacent to the enzyme) for the compounds whose inhibitory eŠect at the maximum concentration was »50z. Since it is impossible to know the exact value of [I] in humans, the maximum conceivable concentration at the time the inhibitor reaches the liver, Iin, max was calculated from the following equation. 4) Since, in the present study, we will discuss drug-drug interactions based on the concentration of protein unbound drugs, the maximum unbound concentration of the inhibitor (I in, max, u ) was calculated by multiplying Iin, max by the blood unbound fraction (fu), and the value obtained was used as an approximation of [I] . In the case of miconazole, Iin, max, u was deˆned as the blood maximum unbound concentration (I max, u ), because miconazole is intravenously administered in most cases.
Iin, max ＝I max ＋ ka×D×Fa Qh k a : absorption rate constant D: dosage Fa: fraction absorbed from the gut to the portal vein Qh: hepatic blood ‰ow Imax: maximum blood concentration of the inhibitor Each parameter was collected from the information described in the references and calculated. Fa was assumed to be 1 to avoid a false negative prediction.
Ka was calculated from the following equations after determining the time to reach the maximum concentra- tion (Tmax) and the half life (t1/2) from the references.
Where kel is the elimination rate constant. Although the value of a blood-to-plasma concentration ratio (RB) is necessary to calculate the unbound fraction in blood (fu), there are few compounds whose RB values have been determined in humans. In this study, we calculated the values of fu using an RB value of 0.575 to avoid a false negative prediction on the assumption that the drugs do not transfer to blood cells (RB value＝1-Hematocrit; the value of 0.425 was used for hematocrit based on human biochemical data). When fu exceeds 1 in this assumption, fu and RB are respectively deˆned as 1 and RB＝fp/fu＝fp. (Where fp is the unbound fraction in plasma.) When the values obtained from the references varied within some range (such as 3 to 7), the median value was to be used. When values were described using an inequality sign (such as À99), the value was used as such. The present prediction was performed on the premise of avoiding a false negative prediction and on the assumption that nateglinide is eliminated only through a metabolic reaction with CYP isozymes.
Results
Preliminary evaluation of nateglinide metabolites showed the ratio of M1 to total metabolites was 62z to 66z in human liver microsomes. Metabolism of nateglinide to M1 in human liver microsomes and the E. coli expression system exhibited Michaelis-Menten ki- netics indicating the involvement of 1 type of enzyme (data not shown). Kinetic parameters of nateglinide metabolism to M1 were obtained from metabolic studies using human liver microsomes and the E. coli expression system ( Table 2 ). The value of Km, app was 68 mM in human liver microsomes and studies on inhibition were conducted using this value. The contribution ratio of CYP2C9 and CYP3A4 to the generation of M1, calculated from kinetic parameters in the E. coli expression system and abundance ratio of CYP2C9 and CYP3A4 in human liver, 17) were 96z and 4z respectively under linear conditions. Hence, we examined the eŠects of various drugs which inhibit the metabolic conversion of nateglinide to M1 using human liver microsomes. Among the inhibitors evaluated, metformin, buformin, aspirin and famotidine did not aŠect the metabolism of nateglinide to M1 at their maximum concentrations (2000 mM for metformin and buformin and 1000 mM for aspirin and famotidine) (Fig. 1) . Although gliclazide, cloˆbrate, carbamazepine and clarithromycin slightly inhibited the catalytic activity at high concentrations, the inhibition did not exceed 50z at their highest concentrations (300 mM for clarithromycin and 1000 mM for gliclazide, cloˆbrate and carbamazepine); as a result the values of IC 50, app for these compounds were not calculated ( Fig. 1 and Table 3 ). Clarithromycin is known to have mechanism-based inhibition (MBI) eŠect against CYP3A4.
18) Therefore, investigation was conducted by determining production activity of M1 after 30 min of preincubation in the presence of b-NADPH at 30 mM in case of clarithromycin. However, decrease in M1 production activity resulted from preincubation was small at 6.4z compared to the cases where nateglinide and clarithromycin were added simultaneously.
The present study conˆrmed that miconazole, nifedipine, rosiglitazone, pioglitazone, gemˆbrozil, ‰ucona-zole, simvastatin, phenylbutazone, bezaˆbrate and ibuprofen inhibited the catalytic activity by up to »50 z in a concentration dependent manner (Fig. 1) . The K i, app values for these 10 compounds were calculated by Dixon plot (Fig. 2) . To adjust the Ki value, we measured unbound fractions in the reaction mixture (fu, in vitro) ( Table 4 ). The fu, in vitro value was approximately 1 for many drugs, and »0.5 for all the drugs, except for simvastatin and miconazole. The free fractions of simvastatin and miconazole were signiˆcantly smaller at 0.073 and 0.199, respectively. The Ki values were calculated by multiplying the unbound fraction in the in vitro experimental system ( Table 4 ). The strongest inhibitor was miconazole followed by simvastatin, nifedipine, rosiglitazone, gemˆbrozil, pioglitazone, ‰uconazole, phenylbutazone, bezaˆbrate and ibuprofen in this order. The 1＋Iin, max, u/Ki values calculated from clinical data were close to 1 for all the compounds examined except for miconazole and ‰uconazole whose corresponding values were 1.56 and 1.22, respectively ( Table  5) .
Discussion
Nateglinide is metabolized in the liver mainly by CYP2C9 and partly by CYP3A4. 1) Our results conrmed the three following points. 1, Investigation using human liver microsomes showed that more than 60z of nateglinide was metabolized to M1. 2, Investigation using the E. coli expression system showed that CYP2C9 was predominantly contributed to the metabolism of nateglinide to M1 at the therapeutic concentrations. 3, Investigation using human liver microsomes showed that the relationship between the concentration of nateglinide and the rate of generation of M1 was similar to Michaelis-Menten kinetics and did not indicate a twophase kinetics. Based on theseˆndings, it was concluded that drug-drug interactions could be predicted by calculating the K i for the inhibitory reaction in human liver microsomes induced in this investigation.
The inhibitors evaluated in this investigation included those that inhibited CYP2C9 and/or CYP3A4 and those without such inhibitory action. Data on the inhibitory eŠect (value of K i or IC 50 ) on the metabolism of a typical substrate by CYP2C9 or CYP3A4 in the experimental system using human liver microsomes were investigated in the literature and are summarized in Table 6 . The inhibitory eŠects of 7 compounds (metfor- min, buformin, gliclazide, cloˆbrate, famotidine, aspirin, and carbamazepine), which exhibited values of IC50, app over 1000 mM in this investigation, on CYP2C9 and CYP3A4 were either not reported or very weak. In addition, either the Ki or IC50 value against CYP2C9 was reported for 9 compounds (ibuprofen, bezaˆbrate, phenylbutazone, ‰uconazole, gemˆbrozil, pioglitazone, rosiglitazone, nifedipine, and miconazole) whose IC50, app values were obtained. Bezaˆbrate, which had a weak inhibitory eŠect on CYP2C9 and CYP3A4 according to data from the literature, exhibited a weak inhibitory eŠect on the conversion of nateglinide to M1 compared to other inhibitory agents. On the other hand, miconazole, which inhibited the conversion of nateglinide to M1 most signiˆcantly in this investigation also exhibited the most signiˆcant inhibitory eŠect on CYP2C9 and CYP3A4 compared to other compounds. These data further supported theˆnding that the strength of CYP isozymes inhibition correlated with that of the inhibition of conversion of nateglinide to Table 4 . K i value of compounds evaluated by in vitro metabolic conversion of nateglinide to M1 in human liver microsomes and ratio of unbound fraction of compounds in the in vitro reaction system Experiments were done in duplicate using pooled microsomes from 10 or 50 individuals. All the data were obtained after oral administration except for miconazole. For miconazole, the I max, u was calculated multiplying f u by the plasma concentration (C max ) right after the 1 hr infusion, and the I max, u was equaled to I in, max, u .
M1. In addition, it was reported that the parent simvastatin compound inhibited CYP3A4, while simvastatin acid that is its active compound inhibited CYP2C9. In this investigation, generation of M1 was signiˆcantly inhibited by simvastatin and it was di‹cult to explain thisˆnding simply by an inhibition of CYP3A4, indicating the possibility that the acid form produced during the reaction also inhibited the metabolism of nateglinide.
With regard to clarithromycin, although in this investigation the IC50, app value was À300 mM, it was not possible to predict a drug-drug interaction based simply on the Ki value considering that clarithromycin exerts an MBI eŠect on CYP3A4. Based on these results, it was concluded that the inhibition of M1 generation due to preincubation was small, and that the MBI activity of clarithromycin on M1 generation was so weak that it could be ignored. This was likely due to the fact that the main CYP involved in metabolism of nateglinide was CYP2C9 and proportion of involvement of CYP3A4 was small. It is necessary to investigate the enhancement of the inhibitory eŠect after preincubation to investigate the possibility of an interaction between nateglinide and a compound with MBI activity. Furthermore, if the eŠect were too signiˆcant to be ignored, a kinetic analysis should be conducted and the interaction should be investigated quantitatively.
The 1＋Iin, max, u/Ki values of the evaluated compounds obtained in this investigation were close to 1, except for the cases of miconazole and ‰uconazole. We used the reported Cmax values, but the actual doses of some drugs are sometimes higher than those described in the reports. For instance, in clinical practice the dose of pioglitazone is 45 mg and that of ‰uconazole is 400 mg. However, since the 1＋Iin, max, u/Ki values of the compounds examined were less than 1.20 excluding miconazole and ‰uconazole, the risk of drug-drug interaction was predicted to be low even if the Iin, max, u values were calculated based on the maximum clinical dosage on the assumption that the plasma concentration increases in a dose-dependent manner. On the other hand, the 1＋ Iin, max, u/Ki value for miconazole was slightly higher at 1.56, possibly suggesting the risk of drug-drug interaction. When the plasma concentration of ‰uconazole is assumed to increase in a dose dependent manner, the values of 1＋I in, max, u /K i are 1.44 and 1.87 for its doses of 200 and 400 mg, respectively, possibly suggesting the risk of a drug-drug interaction between ‰uconazole and nateglinide in clinical situations.
Several clinical studies on the combined use of nateglinide with other drugs have been performed. Among the compounds examined in this study, there have been clinical reports of concomitant uses of metformin and ‰uconazole with nateglinide. The combined use of metformin (500 mg) with nateglinide (120 mg) does not aŠect the AUC nor the C max of nateglinide. 37) Our result conˆrmed those results demonstrating that metformin hardly inhibits the metabolism of nate- glinide. It was reported that pretreatment with ‰ucona-zole at a daily dose of 200 mg for 4 days (however, 400 mg on Day 1) increased the AUC of nateglinide by 48z when nateglinide was orally administered at a dose of 30 mg. 38) In this study, the 1＋Iin, max, u/Ki value was 1.44 when the dose of ‰uconazole was 200 mg, suggesting the risk of drug-drug interaction and conˆrming theˆnd-ings of the clinical report.
In conclusion, the present method can predict the risk of the drug-drug interaction through CYPs to some degree. The study results show that the estimated value of 1＋Iin, max, u/Ki for various compounds was generally low and the risk of a drug interaction with nateglinide through CYPs was most likely to be low, except for miconazole and ‰uconazole that are strong inhibitors of CYP isozymes.
